New Delhi, April 3 -- India is struggling with a rapid surge in type 2 diabetes and obesity. With the expiry of the patent for semaglutide, popularly known by the brand names Ozempic and WeGovy, and the entry of generic medications, we are now at an inflection point in diabetes and obesity care.

As per recent reports, over 40 pharmaceutical companies are expected to introduce generic versions of semaglutide in the near future. Though this will offer hope to many people, experts advise staying vigilant, as access and affordability must go hand in hand with safety, awareness, and responsible use.

Also, though newer versions tend to contain the same active molecule, keep in mind that semaglutide is a complex molecule at its core. Even mino...